Previous experimental studies have highlighted that citrulline (CIT) could be a promising pharmaconutrient. However, its pharmacokinetic characteristics and tolerance to loading have not been studied to date. The objective was to characterise the plasma kinetics of CIT in a multiple-dosing study design and to assess the effect of CIT intake on the concentrations of other plasma amino acids (AA). The effects of CIT loading on anabolic hormones were also determined. Eight fasting healthy males underwent four separate oral loading tests (2, 5, 10 or 15 g CIT) in random order. Blood was drawn ten times over an 8 h period for measurement of plasma AA, insulin and growth hormone (Gh). Urine samples were collected before CIT administration and over the next 24 h. None of the subjects experienced side effects whatever the CIT dose. Concerning AA, only CIT, ornithine (ORN) and arginine (ARG) plasma concentrations were affected (maximum concentration 146 (SEM 8) to 303 (SEM 11) mmol/l (ARG) and 81 (SEM 4) to 179 (SEM 10) mmol/l (ORN); time to reach maximum concentration 1·17 (SEM 0·26) to 2·29 (SEM 0·20) h (ARG) and 1·38 (SEM 0·25) to 1·79 (SEM 0·11) h (ORN) according to CIT dose). Even at high doses, urinary excretion of CIT remained low (,5 %). Plasma insulin and Gh were not affected by CIT administration. Short-term CIT administration is safe and well-tolerated. CIT is a potent precursor of ARG. However, at the highest doses, CIT accumulated in plasma while plasma ARG levels increased less than expected. This may be due to saturation of the renal conversion of CIT into ARG.
Citrulline (CIT) is an amino acid whose name is derived from Citrullus vulgaris (commonly known as watermelon) from which it was first isolated in the 1930 s (for a recent review, see Curis et al. (1) ). Until recently, CIT had not attracted much interest in the scientific community because (i) it is a non-proteic amino acid and (ii) it was considered only as an intermediate of the urea cycle (2) . In the early 1980 s, Windmueller & Spaeth (3) demonstrated that the small intestine releases large amounts of CIT which is mainly taken up by the kidney (of note, CIT is not taken up by the liver) and, in turn, arginine (ARG) was released in amounts equivalent to about 75 % of the CIT taken up. Then, Castillo et al. (4, 5) were the first to characterise the CIT and ARG in vivo kinetics at the whole-body level in healthy subjects. These findings allowed the suggestion of an ARG -CIT -ARG inter-organ cycle which can be seen (6) as a mechanism for protecting dietary ARG from excessive liver degradation (because CIT is not taken up by the liver (7) ) and thus maintaining protein homeostasis. Concurrently, it was also demonstrated that CIT was the endproduct of the NO synthase reaction (8) .
The role of the intestine as a key regulator of CIT production was further emphasised in situations where intestinal function is altered (i.e. short-bowel syndrome, coeliac disease, radiation-induced intestinal damage, etc) (9 -13) . In situations where ARG synthesis is compromised, CIT becomes a conditionally essential amino acid (14) , thus justifying dietary supplementation with ARG. The specificities of CIT and ARG metabolism combined with the fact that CIT is a major precursor of ARG (through renal conversion) (1, 6) led several authors to suggest that CIT might be particularly useful for patients with impaired ARG metabolism (15 -19) . These data led us to raise the hypothesis that CIT, not ARG, should be administered when intestinal function is compromised. Applying this concept, we recently demonstrated that CIT (but not ARG) increases ARG pools and restores N balance after massive intestinal resection in the rat (20) . Because malnutrition in aged animals leads to gut atrophy (21) , we extended the concept to refeeding in old malnourished rats. In this model, CIT supplementation increased protein content in the muscle by stimulating protein synthesis (22) . These data form a strong rationale for conducting clinical trials on the effects of CIT supplementation in short-bowel-syndrome patients or in elderly malnourished patients. However, a prerequisite to any clinical study is the evaluation of the tolerance to CIT loading and the determination of pharmacokinetic parameters (maximum concentration (C max ), time to reach maximum concentration (t max ), metabolic clearance, etc) in healthy subjects. In this matter, data are scarce and the available articles are either preliminary (23) or suffer limitations (24) as discussed elsewhere (25) . The results obtained by administration of its food source (i.e. watermelon) (26) were inconclusive since CIT content in watermelon varies strongly according to species and maturity (27) . Several studies have reported that CIT plasma concentration is rapidly increased after oral load (18,28 -30) , but there is little data available on the transporters involved in intestinal absorption of CIT (31) . Moreover, the absorption of amino acids related to CIT (i.e. ARG and ornithine (ORN)) is low, leading to gastrointestinal side effects (i.e. diarrhoea and vomiting) at relatively high intake levels (i.e. . 10 g in the bolus) (32) but nothing is known about tolerance to CIT when administered at high dosages.
The aim of the present study was to determine the tolerance and the pharmacokinetic parameters of increasing loads of CIT (2, 5, 10 and 15 g) in healthy young subjects, and to investigate the impact on hormonal secretions, since CIT metabolites (for example, ARG, ORN) are known to have strong secretagogue effects (33 -35) .
Materials and methods
The study was approved by the ethics committee of the Hôtel-Dieu Hospital (Paris, France). All volunteers gave written informed consent after a full explanation of the study. Enrolment and management of subjects was performed by ASTER (Paris, France), which is a for-profit institution authorised by the French Ministry of Health to perform experiments on healthy volunteers.
Study design
Subjects. The study was performed on eight young healthy male volunteers (age 27·6^1·5 years; BMI 22·3^0·5 kg/m 2 ). All volunteers were given a medical check-up to ensure they had no acute or chronic diseases or signs of infection and inflammation; none of the subjects were taking any medication liable to affect amino acid metabolism. They were screened by physical examination, blood tests, urinary analysis and electrocardiogram. All volunteers received a normoproteic diet during the week before the beginning of the study and throughout the study.
Protocol. All volunteers received four oral loads consisting of 2, 5, 10 or 15 g CIT administered in random order, each load being separated by a washout period of 15 d. CIT was dissolved into 150 ml water and the solution was drunk rapidly. The glass was washed by 50 ml water which was rapidly drunk by the volunteers. The doses are similar to those used for other related amino acids (i.e. ARG, ORN) in previous pharmacokinetic (34, 36) and therapeutic studies (37 -39) . Blood samples were drawn before administration (considered as time 0) and at 0·25, 0·5, 0·75, 1, 1·5, 2, 3, 5 and 8 h after the loads. Urine samples were collected in vessels containing antiseptic, during the 0-8 h period and then at 16 and 24 h post-administration. Haematological markers (leucocytes, polymorphonuclears, lymphocytes, monocytes, erythrocytes, Hb) and biochemical markers (Ca, total proteins, albumin, C-reactive protein, urea, creatinine, glucose, cholesterol, TAG) were determined before and after the study period. Pre-and post-study clinical examinations were also performed. Safety was evaluated by measurement of arterial pressure and an electrocardiogram was performed before and at 1, 2, 4 and 8 h after CIT administration.
Measurements
Plasma and urine amino acid concentration. Urine samples taken over the 8 h were carefully homogenised. Blood and urine samples were rapidly centrifuged and deproteinised with a 30 % (w/v) sulfosalicylic acid solution. The supernatant fractions were stored at 2 808C for analysis of amino acids.
Amino acids were separated and quantified by ion exchange chromatography using an amino acid autoanalyser (Amino Tac, JLC-500/V; Jeol Ltd, Tokyo, Japan) with ninhydrin derivatisation (40) . Our participation in the European Quality Control Scheme (ERNDIM) indicates the accuracy of our amino acid determinations.
Nitrogen excretion. N was quantified by chemiluminescence (41) on an Antek 9000 apparatus (Antek, Houston, TX, USA).
Plasma insulin and growth hormone concentrations. These were determined using commercial RIA kits; insulin by a INSIK-5 kit (DiaSorin, Antony France) and growth hormone by an hGH-RIACT kit (Cis-Bio International, Gif-surYvette, France).
Other plasma parameters. Blood samples were rapidly centrifuged, and plasma concentrations of creatinine, Ca and glucose were determined using an Olympus AU 600 analyser (42) .
Pharmacokinetics and statistical analysis
Plasmatic pharmacokinetic parameters. Pharmacokinetic analysis was performed on the plasma concentration -time data. Pharmacokinetic parameters were estimated using the R software package (R Foundation for Statistical Computing, Vienna, Austria (43) ). Data were analysed with a non-compartmental model with no lag time. The apparent elimination rate constant (k e ) was estimated by non-linear least-squares regression on the last part of the C(t) curve. A shifted exponential decay model following the equation:
was fitted to the data using a 1/C 2 weighting scheme. Three models were tested with the additive constant B taken either as a fit adjustment parameter, as a constant estimated as the minimum concentration measured for each curve, or as a constant estimated as the mean of the minimum concentrations for each subject. The Akaike (44) information criterion was used to discriminate between models yielding coefficients significant at P,0·01. The Akaike information criterion based on information theory is useful for comparing models fitted with different numbers of parameters and different numbers of data points as it takes into account not only goodness of fit but also degrees of freedom, thus discouraging overfitting. In order to only fit the data when the exponential decay model was valid (i.e. to select the starting time of the 'last part of the curve' used for the non-linear model fitting), a procedure was written in R programming language to test different time-lengths for the last part of the curve. For each curve we varied the start time of the exponential fit from 0·75 h to 1·5 h and the end time from 5 h to 8 h, which yielded five fits including between five and seven experimental points. The Akaike information criterion was used to select the optimal range to fit each curve.
The area under the curve (AUC) for the time 0-8 h (AUC 0 -8 ) was calculated by the trapezoidal rule. The AUC from the last experimental time to infinity (AUC 821 ) was calculated by extrapolation, dividing the last measured plasma concentration value by the apparent elimination rate constant (k e ). The AUC 021 was calculated by adding AUC 0 -8 and AUC 821 . All AUC corrected for baseline concentration, which was taken as the concentration at t ¼ 0 h, are termed DAUC.
AUC 0 -8 was smoothed by cubic spline interpolation and the interpolated curve was derived numerically in order to obtain a smoothed C(t) curve. C max and t max were deduced from this smoothed C(t) curve. All C max corrected for baseline concentration are termed DC max .
Clearance (Cl) was evaluated as Cl ¼ dose/DAUC 021 . Apparent distribution volume (V d ) was computed as Cl/k e . The apparent half-life of elimination (t 1/2 ) was calculated as t 1/2 ¼ ln2/k e .
Urinary pharmacokinetic parameters. Renal clearance (Cl R ) was computed for CIT and creatinine (CR). Renal clearance (Cl R ) of a given solute was estimated as U £ V/P were U is the solute urine concentration for the 0-8 h period, V is the urine flow rate for the same period and P is the average plasma solute concentration, taken as AUC 0 -8 /8, with AUC 0 -8 not corrected for the baseline concentration.
Fractional CIT reabsorption rate (Fr CIT ) was computed as: Retention percentage (RP) of CIT was computed as:
where U is as above and Q 0 -8 is the urine volume collected during the 0-8 h period.
Statistical analysis. Three factors were considered for the analysis: dose, patient and period of administration. The experiments followed a double Latin square design assuming an additive model and no interaction between the two squares. Three-factor ANOVA followed by Tukey's honestly significant differences post hoc test was used to estimate effects of each of the three factors on all the above computed plasma or urinary pharmacokinetic parameters. Tests were applied to natural logarithm-transformed values of DC max , DAUC and urinary excretion values, in order to homogenise variances.
When ANOVA showed a significant dose effect, dose proportionality was tested and, as shown in the results section, only when a linear relationship was significant. In relation to amino acid metabolism we also tested the t max values ordering for the three amino acids CIT, ORN and ARG by applying one-sided t tests.
Results
All eight subjects completed all four trials. There was no dropout or subject replacement.
Tolerance
None of the volunteers suffered nausea or diarrhoea or any other side effect, whatever the dose.
Safety
A clinical and biological check-up (see Material and Methods section) was performed in order to evaluate the potential adverse effects of CIT. CIT administration had no effect on haematological or biochemical markers nor on blood pressure (data not shown). Moreover, no clinical symptoms were noticed during the present study (data not shown).
Plasma amino acids
Citrulline. Following CIT administration, plasma CIT concentration increased to a maximum (C max ) then decreased to baseline levels within 3-5 h (Fig. 1) . From the eight sets of volunteer data, t max remained constant at an average of 42 min for the 2, 5 and 10 g loads and shifted to an average 56 min for the 15 g load (P¼6 £ 10 25 ). The DC max , DAUC 0 -8 and DAUC 021 of CIT changed significantly with increasing dose (P,0·001 after natural logarithm transformation) (Fig. 2) . Of note, this increase was not proportional to the load.
CIT clearance was dependent on load in the load range 2-10 g (P, 0·001); however, there were no differences between clearances for the 10 g and 15 g doses.
There were no changes in the apparent distribution volume of CIT, whatever the load.
Apparent elimination half-life (t 1/2 ) increased linearly with increasing doses (P, 0·001) for the load range 2-15 g (Table 1 ).
Arginine and ornithine. After CIT administration, plasma ARG and ORN concentrations increased to reach a maximum (between 1·17 (SEM 0·26) and 2·29 (SEM 0·20) h for ARG and between 1·38 (SEM 0·25) and 1·79 (SEM 0·20) h for ORN according to CIT load) and then decreased without reaching baseline values at the end of the 8 h period. Noise and lack of pure exponential decay at the last part of the curve meant that we could not compute elimination constants and thus half-life time, DAUC 021 and clearance for these amino acids. Hence, only DAUC 0 -8 , DC max and t max were computed for ARG (Table 2 ) and ORN (Table 3 ). Natural logarithms of DAUC 0 -8 were clearly modified with the load (P, 0·001), except for ORN under the 15 g load (Fig. 2) , as were natural logarithms of DC max (P,0·001), except for ARG and ORN at the 15 g CIT load. However, because of noise, a load effect on t max could only be detected for ARG (P¼0·007) and not for ORN. For each CIT load, t max was greater for ARG than for CIT (P¼0·04, P¼0·0035, P, 0·001 and P, 0·001 for loads of 2, 5, 10 and 15 g, respectively).
Other amino acids. CIT administration led to no significant changes in other amino acid concentrations compared with baseline values (Table 4) . Hormones. Plasma insulin and growth hormone were not affected by CIT administration, whatever the load (data not shown).
Urinary amino acids. CIT, ARG and ORN excretion increased significantly during the studied period (0 -8 h), and the increases were related to load administered (P,0·001 after natural logarithm transformation for CIT, ARG and ORN) (Table 5 ). However, urinary output returned to physiological values later on (i.e. 8-24 h) (data not shown).
Mass balance between CIT load and the urinary excretion of CIT, ARG and ORN revealed that only a small fraction of CIT load is excreted, as shown by the retention percentage (98·6 -86·7 %). CIT retention was significantly dependent on load (P,0·001) (Table 5) , decreasing with higher loads.
Fractional CIT reabsorption rate (Fr CIT ) was very high (99·0-91·9 %) and was significantly dependent on load (P,0·001) (Table 5 ), but decreased with higher loads.
Urinary calcium and nitrogen. CIT administration had no effect on total N and Ca excretion (Table 5) .
Discussion
CIT has recently begun to attract attention in clinical nutrition. Indeed, the CIT molecule appears to be an accurate marker of intestinal (45) or renal failure (46) . Moreover, experimental results indicate that CIT could be a promising therapeutic agent for promoting protein synthesis (47) . However, its safety, tolerance and most appropriate dose need to be determined as a prerequisite to any use in humans (25) . The present study clearly showed that CIT is well tolerated (no side effects), and it should be underlined that CIT did not induce gastrointestinal disorders at high dose (i.e. 15 g). This latter result is quite surprising because a bolus (. 10 g) of related amino acids such as ORN or ARG usually causes diarrhoea (32, 33) . It can be explained by rapid saturation of the intestinal absorption of ORN and ARG, which induce osmotic diarrhoea at high loads (32) . This difference in behaviour between CIT and ORN and ARG suggests that intestinal absorption of CIT is not a limiting step, even at high CIT loads (i.e. .10 g). Of note, if CIT transport in several cell types (for example, endothelial cells and macrophages) is well characterised in several studies (48, 49) , intestinal CIT absorption is poorly documented (31) . Nevertheless, data discussed above strongly suggest that there may be a specific powerful carrier of CIT. This idea is supported by our recent work (performed using Caco-2 cells) which demonstrated that CIT uptake is mediated by two different mechanisms, one of them being clearly different to classical cationic amino acid transporters and displaying high V max (50) . Concerning the safety of CIT after acute administration, a major potential concern is the fact that excretion of amino acids in large amounts in urine is associated with an increase Table 1 . Pharmacokinetic parameters of plasma citrulline after citrulline loads administered to healthy volunteers* (Mean values with their standard errors) ANOVA and Tukey's honestly significant differences test were performed on t max , ln(DC max ) and ln(DAUC 0 -8 ).
in urinary Ca loss, and it has been shown that the dose of amino acids administered is correlated with the renal excretion of Ca (51) . This phenomenon may be a problem in the long term because amino acid-induced Ca loss may be responsible for osteoporosis. In the present study, calciuria remained constant whatever the urinary concentration of CIT, which suggests that CIT administration is not expected to interfere with Ca homeostasis. Of note, similarly to intestinal absorption, renal CIT reabsorption appears extremely powerful because urinary loss is very low (,5 %) even at high CIT intake.
Following the CIT loads, plasma CIT concentration increased rapidly and massively (10-fold at the 2 g load to 100-fold at the 15 g load) and returned to baseline values within 5-8 h post-loading.
A review of the literature data indicates that the pharmacokinetic parameters of CIT are similar to those of related amino acids (such as ARG and ORN) (33 -35) , except for C max which is several-fold higher with CIT than with ARG (36) or ORN (35) . This result is in agreement with a previous study of Rajantie et al. (23) , who observed that CIT loads caused much greater increases in its plasma concentration than equimolar loads of ARG or ORN. This difference is probably related to the specific metabolism of CIT. A large proportion of dietary ARG (or ORN) is extracted during the first-pass splanchnic extraction (ARG is degraded by the intestine to yield ORN and proline (52) , and in the liver ARG is a substrate for ureagenesis (5,29,36,53 -55) ). CIT, however, bypasses splanchnic extraction that renal ARG synthesis becomes saturated. This is confirmed by the increase in urinary ARG excretion and the decrease in both CIT retention percentage and fractional reabsorption rate at this high CIT intake. It should also be underlined that no other amino acid concentrations were modified by CIT administration, which is in agreement with our previous experimental studies (20, 22) . This means that CIT is a very 'neutral' amino acid performing a specific job in terms of ARG metabolism.
We also measured hormonal patterns because the results of several studies have shown the ability of CIT to modify plasma insulin levels (22) or stimulate insulin secretion (58) . However, we observed no modification of plasma insulin and growth hormone concentrations in the present study. This may be explained by the fact that the volunteers were studied in the fasted state. Of note, it has previously been shown that the secretagogue properties of ORN (as ketoglutarate salt) are more pronounced in the fed state than in the fasted state (34, 35) .
In conclusion, the present study in healthy men provides important data on CIT safety and tolerance, which both appear excellent and better than related amino acids (i.e. ARG and ORN), at least in the short term. It would be of interest to perform such a pharmacokinetic study after chronic exposure to CIT because a number of enzymes involved in CIT metabolism may be subject to long-term regulation.
The present pharmacokinetic study confirms our previous experimental data showing that CIT is an excellent ARG precursor at the whole-body level. Finally, the pharmacokinetic parameters suggest that saturation begins to occur at a load of 15 g, and therefore a 10 g dose should be the most appropriate for use in clinical practice.
